scholarly journals Mecillinam: a low-risk antimicrobial agent for induction of Clostridium difficile infection in an in vitro human gut model

2009 ◽  
Vol 63 (4) ◽  
pp. 838-839 ◽  
Author(s):  
S. D. Baines ◽  
R. O'Connor ◽  
G. Huscroft ◽  
K. Saxton ◽  
J. Freeman ◽  
...  
Keyword(s):  
Clostridium Difficile ◽  
Antimicrobial Agent ◽  
Clostridium Difficile Infection ◽  
Low Risk ◽  
Human Gut

scholarly journals Evaluation of linezolid for the treatment of Clostridium difficile infection caused by epidemic strains using an in vitro human gut model

2011 ◽  
Vol 66 (7) ◽  
pp. 1537-1546 ◽  
Author(s):  
S. D. Baines ◽  
A. R. Noel ◽  
G. S. Huscroft ◽  
S. L. Todhunter ◽  
R. O'Connor ◽  
...  
Keyword(s):  
Clostridium Difficile ◽  
Clostridium Difficile Infection ◽  
Human Gut

scholarly journals Evaluation of NVB302 versus vancomycin activity in an in vitro human gut model of Clostridium difficile infection

2012 ◽  
Vol 68 (1) ◽  
pp. 168-176 ◽  
Author(s):  
G. S. Crowther ◽  
S. D. Baines ◽  
S. L. Todhunter ◽  
J. Freeman ◽  
C. H. Chilton ◽  
...  
Keyword(s):  
Clostridium Difficile ◽  
Clostridium Difficile Infection ◽  
Human Gut

scholarly journals Probing Clostridium difficile Infection in Complex Human Gut Cellular Models

2019 ◽  
Vol 10 ◽  
Author(s):  
Blessing O. Anonye ◽  
Jack Hassall ◽  
Jamie Patient ◽  
Usanee Detamornrat ◽  
Afnan M. Aladdad ◽  
...  
Keyword(s):  
Clostridium Difficile ◽  
Clostridium Difficile Infection ◽  
Human Gut ◽  
Cellular Models

scholarly journals Evaluation of antimicrobial activity of ceftaroline against Clostridium difficile and propensity to induce C. difficile infection in an in vitro human gut model

2013 ◽  
Vol 68 (8) ◽  
pp. 1842-1849 ◽  
Author(s):  
S. D. Baines ◽  
C. H. Chilton ◽  
G. S. Crowther ◽  
S. L. Todhunter ◽  
J. Freeman ◽  
...  
Keyword(s):  
Antimicrobial Activity ◽  
Clostridium Difficile ◽  
Human Gut

scholarly journals Reducing risk of Clostridium difficile infection and overall use of antibiotic in the outpatient treatment of urinary tract infection

2018 ◽  
Vol 10 (10) ◽  
pp. 283-293 ◽  
Author(s):  
Ivy Y. Ge ◽  
Helene B. Fevrier ◽  
Carol Conell ◽  
Malika N. Kheraj ◽  
Alexander C. Flint ◽  
...  
Keyword(s):  
Urinary Tract Infection ◽  
Urinary Tract ◽  
High Risk ◽  
Clostridium Difficile ◽  
Tract Infection ◽  
Antibiotic Treatment ◽  
Clostridium Difficile Infection ◽  
Case Control ◽  
Low Risk ◽  
Moderate Risk

Background: Risk of community-acquired Clostridium difficile infection (CA-CDI) following antibiotic treatment specifically for urinary tract infection (UTI) has not been evaluated. Methods: We conducted a nested case-control study at Kaiser Permanente Northern California, 2007–2010, to assess antibiotic prescribing and other factors in relation to risk of CA-CDI in outpatients with uncomplicated UTI. Cases were diagnosed with CA-CDI within 90 days of antibiotic use. We used matched controls and confirmed case-control eligibility through chart review. Antibiotics were classified as ciprofloxacin (most common), or low risk (nitrofurantoin, sulfamethoxazole/trimethoprim), moderate risk, or high risk (e.g. cefpodoxime, ceftriaxone, clindamycin) for CDI. We computed the adjusted odds ratios (ORs) and 95% confidence intervals (CIs) for the relationship of antibiotic treatment for uncomplicated UTI and history of relevant gastrointestinal comorbidity (including gastrointestinal diagnoses, procedures, and gastric acid suppression treatment) with risk of CA-CDI using logistic regression analysis. Results: Despite the large population, only 68 cases were confirmed with CA-CDI for comparison with 112 controls. Female sex [81% of controls, adjusted odds ratio (OR) 6.3, CI 1.7–24), past gastrointestinal comorbidity (prevalence 39%, OR 2.3, CI 1.1–4.8), and nongastrointestinal comorbidity (prevalence 6%, OR 2.8, CI 1.4–5.6) were associated with increased CA-CDI risk. Compared with low-risk antibiotic, the adjusted ORs for antibiotic groups were as follows: ciprofloxacin, 2.7 (CI 1.0–7.2); moderate-risk antibiotics, 3.6 (CI 1.2–11); and high-risk antibiotics, 11.2 (CI 2.4–52). Conclusions: Lower-risk antibiotics should be used for UTI whenever possible, particularly in patients with a gastrointestinal comorbidity. However, UTI can be managed through alternative approaches. Research into the primary prevention of UTI is urgently needed.

scholarly journals Effectiveness of a short (4 day) course of oritavancin in the treatment of simulated Clostridium difficile infection using a human gut model

2012 ◽  
Vol 67 (10) ◽  
pp. 2434-2437 ◽  
Author(s):  
C. H. Chilton ◽  
J. Freeman ◽  
G. S. Crowther ◽  
S. L. Todhunter ◽  
M. H. Wilcox
Keyword(s):  
Clostridium Difficile ◽  
Clostridium Difficile Infection ◽  
Human Gut
Sign in / Sign up

Export Citation Format

Share Document